Status:
UNKNOWN
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Spinocerebellar Ataxia Type 3
Machado-Joseph Disease
Eligibility:
All Genders
18+ years
Brief Summary
The study will consist of a prospective observation of subjects in a natural history design. The investigators will monitor changes of clinical scales, quality of life, messenger ribonucleic acid (mRN...
Detailed Description
Spinocerebellar ataxia type 3, or Machado-Joseph disease (SCA3/MJD), is an autosomal dominant neurodegenerative disorder caused by a CAG expansion at ATXN3. The gene product is a 42kDa protein called ...
Eligibility Criteria
Inclusion
- Individuals with molecular diagnosis of SCA3/MJD
- Individuals at 50% risk of inheriting SCA3/MJD mutation without any clinical manifestation
Exclusion
- Refusal to sign informed consent
- Other diagnosed neurological conditions;
- Diabetes Mellitus;
- Chronic allergy (asthma, eczema, urticaria)
- Eosinophilia on baseline
Key Trial Info
Start Date :
March 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT04419974
Start Date
March 18 2017
End Date
August 1 2021
Last Update
June 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903